Trial Profile
A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary (CUP): incorporating the prospective validation of molecular classifiers in diagnosis and classification and exploratory metabonomics
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Epirubicin (Primary)
- Indications Cancer; Carcinoma
- Focus Biomarker; Diagnostic use
- Acronyms CUP ONE
- 24 Oct 2023 Results comparing a 92-gene assay GEP versus centralized IHC (C-IHC; 10 markers), presented at the 48th European Society for Medical Oncology Congress.
- 02 Apr 2019 Status changed from active, no longer recruiting to completed.
- 13 Dec 2013 Accrual to date is 114% according to United Kingdom Clinical Research Network.